surely non final rejections in such early days of a patent application is just to be expected. Very hard to see how patents for veyonda as an adjunct to immunotherapy would be rejected when patents for it as an adjunct to other therapies has been approved.
Ann: Veyonda and Opdivo IONIC Study First Patient Dosed, page-33
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.8¢ |
Change
-0.017(14.8%) |
Mkt cap ! $28.63M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 9.8¢ | $70.79K | 680.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25356 | 9.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 240399 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| NOX (ASX) Chart |